Roche's CT-388 Adds Optionality In The GLP Market, But Wait For Dips [Seeking Alpha]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Seeking Alpha
Roche's Genentech plans to start its Phase 3 this quarter, but primary completion will happen by 2028. Thus, this new GLP bet is inherently still a long-term thesis, and approval is always uncertain until we have more robust Phase 3 data. Still, Roche is building a two-mechanism platform with CT-388 (incretin) plus petrelintide (amylin). I believe this would give it great efficacy and better tolerability/durability among GLP competitors. So, I am long-term bullish on Roche, but ideally it's a buy on dips. Elena Safonova/iStock via Getty Images Roche Holding AG ( RHHBY ) presented, via its US subsidiary Genentech, the Phase 2 results for CT-388. This is a once-weekly dual GLP-1/GIP receptor agonist, and its trial was conducted in adults with obesity or overweight without type This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche (OTCMKTS:RHHBY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Genentech Awards Grant to Support Science Center's Translation ProjectPR Web
- SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal [Yahoo! Finance]Yahoo! Finance
- Pharmaceutical Contract Development and Manufacturing Organization Forecasts Report 2026: A $374.68 Billion Market by 2031 - One-Stop CDMOs, Rapid AI Platforms, and GLP-1/HPAPI Build-Outs Drive Demand [Yahoo! Finance]Yahoo! Finance
- Genentech in up to $1.7B RNAi licensing deal with SanegeneBio [Seeking Alpha]Seeking Alpha